FLAURA2 Results Demonstrate Osimertinib Plus Chemotherapy Superior Compared to Osimertinib Alone
Osimertinib plus chemotherapy demonstrated a statistically significant and clinically meaningful progression-free survival benefit compared to osimertinib alone, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World...
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Tags: TRI Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Pharmaceuticals | Statistics | Study